NCT05151848View on ClinicalTrials.gov

Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

January 15, 2026

Study Completion Date

January 15, 2026

Conditions
Takayasu Arteritis
Interventions
DRUG

Adalimumab Injection

Adalimumab Injection injected subcutaneously every other week for 78 weeks

DRUG

Tofacitinib 5 MG

Tofacitinib 5 MG BID taken orally for 78 weeks

Trial Locations (4)

100000

RECRUITING

Beijing Anzhen Hospital, Beijing

NOT_YET_RECRUITING

The General Hospital of the People's Liberation Army, Beijing

100053

NOT_YET_RECRUITING

Beijing Shijitan Hospital, Beijing

NOT_YET_RECRUITING

Beijing Xuanwu Hospital, Beijing

All Listed Sponsors
lead

Chinese SLE Treatment And Research Group

OTHER